US EditionCB21 Pharma Successfully Passes Certification Audit for Dronabinol Manufacturing - Business of Cannabis
Summary by Business of Cannabis
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
CB21 Pharma Successfully Passes Certification Audit for Dronabinol Manufacturing - Business of Cannabis
CB21 Pharma, a leading pharmaceutical company focused on developing and marketing innovative cannabinoid-based treatments, is pleased to announce the successful completion of its certification audit for manufacturing plant-derived Dronabinol by the State Institute for Drug Control (SÚKL). This marks a significant milestone in the company’s efforts to expand its portfolio of medical cannabis-derived APIs for patients suffering from various medica…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
